By Mariam Sunny (Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Shares of Eli Lilly and Company LLY gained 2.7% on reports emerging that a major collaboration deal worth up to $1.3 billion with Superluminal Medicines to develop obesity and cardiometabolic ...